Compare iShares China Large-Cap ETF (FXI) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? iShares China Large-Cap ETF trades at $33.93 (market cap $3.90B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.47B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 2.2× iShares China Large-Cap ETF's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 151 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FXI | HNGE | |
|---|---|---|
Market Cap | $3.90B | $8.47B |
Volume | 21,620,520 | 1,624,526 |
52-Week High | $41.08 | $105.14 |
52-Week Low | $31.59 | $31.17 |
Typical Hold Time | 151 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $34.17 with minimal daily movement (+0.09%). The technical picture is bearish with moving averages signaling caution, though oscillators are neutral. Recent news highlights China's economic challenges including industrial overcapacity and weak domestic consumption, while corporate profits surged 26% in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E of 11.10 versus the S&P 500's 22.54, offering potential value amid high political risk.
FXI presents a contrarian opportunity for investors seeking China exposure at discounted valuations, but faces substantial headwinds from U.S.-China tensions and domestic economic rebalancing. The ETF's heavy financial sector weighting and state-backed monetary support provide stability, though momentum remains weak. Key risks include escalating trade protectionism and China's export control uncertainties.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
